View Item 

Show simple item record

Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout
dc.contributor.authorFitzGerald, John D.
dc.contributor.authorMikuls, Ted R.
dc.contributor.authorNeogi, Tuhina
dc.contributor.authorSingh, Jasvinder A.
dc.contributor.authorRobbins, Mark
dc.contributor.authorKhanna, Puja P.
dc.contributor.authorTurner, Amy S.
dc.contributor.authorMyslinski, Rachel
dc.contributor.authorSuter, Lisa G.
dc.date.accessioned2018-05-15T20:13:19Z
dc.date.available2019-07-01T14:52:17Zen
dc.date.issued2018-05
dc.identifier.citationFitzGerald, John D.; Mikuls, Ted R.; Neogi, Tuhina; Singh, Jasvinder A.; Robbins, Mark; Khanna, Puja P.; Turner, Amy S.; Myslinski, Rachel; Suter, Lisa G. (2018). "Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout." Arthritis Care & Research 70(5): 659-671.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/143639
dc.publisherWiley Periodicals, Inc.
dc.publisherRand Corporation
dc.titleDevelopment of the American College of Rheumatology Electronic Clinical Quality Measures for Gout
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143639/1/acr23500.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143639/2/acr23500-sup-0001-AppendixS1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/143639/3/acr23500_am.pdf
dc.identifier.doi10.1002/acr.23500
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceBecker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment‐failure gout. J Rheumatol 2009; 36: 1041 – 8.
dc.identifier.citedreferenceLoebl WY, Scott JT. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974; 33: 304 – 7.
dc.identifier.citedreferenceNuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006; 8 Suppl 1: S1.
dc.identifier.citedreferenceProwse RL, Dalbeth N, Kavanaugh A, Adebajo AO, Gaffo AL, Terkeltaub R, et al. A Delphi exercise to identify characteristic features of gout: opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol 2013; 40: 498 – 505.
dc.identifier.citedreferenceAnnemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000‐2005. Ann Rheum Dis 2008; 67: 960 – 6.
dc.identifier.citedreferenceSarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12: 61 – 5.
dc.identifier.citedreferenceKlasco RS, Glinert LH. Language for actionable recommendations in clinical guidelines: avoiding hedging and equivocation. JAMA 2017; 317: 583 – 4.
dc.identifier.citedreferenceStamp L, Sharples K, Gow P, Raill B. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30: 567 – 72.
dc.identifier.citedreferenceSingh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007; 57: 822 – 9.
dc.identifier.citedreferenceSingh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009; 68: 1265 – 70.
dc.identifier.citedreferenceStone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889 – 934.
dc.identifier.citedreferenceBonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A 1C. Diabetes Care 2011; 34 Suppl 2: S184 – S90.
dc.identifier.citedreferenceNational Quality Forum. Comprehensive diabetes care: hemoglobin A1c (HbA 1c ) control (<8.0%). Quality positioning system (QPS) measure description display information. 2015. URL: http://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=944&print=0&entityTypeID=1.
dc.identifier.citedreferencePerez‐Ruiz F, Herrero‐Beites AM, Carmona L. A two‐stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis. Arthritis Rheum 2011; 63: 4002 – 6.
dc.identifier.citedreferenceLoeb JN. Influence of temperature on solubility of monosodium urate. Arthritis Rheum 1972; 15: 189 – 92.
dc.identifier.citedreferenceKhanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 – 61.
dc.identifier.citedreferenceNational Quality Forum. Measure evaluation criteria. 2015. URL: http://www.qualityforum.org/Measuring_Performance/Submitting_Standards/Measure_Evaluation_Criteria.aspx.
dc.identifier.citedreferenceQaseem A, Harris RP, Forciea MA, and the Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Summaries for patients. Ann Intern Med 2017; 166: 58 – 68.
dc.identifier.citedreferenceMedicine Io. Standards for developing trustworthy clinical practice guidelines (CPGs). Clinical practice guidelines we can trust. 2011. URL: http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2011/Clinical-Practice-Guidelines-We-Can-Trust/Clinical%20Practice%20Guidelines%202011%20Insert.pdf.
dc.identifier.citedreferenceMcLean RM. The long and winding road to clinical guidelines on the diagnosis and management of gout [editorial]. Ann Intern Med 2017; 166: 73 – 4.
dc.identifier.citedreferenceFitzGerald JD, Neogi T, Choi HK. Editorial: do not let gout apathy lead to gouty arthropathy. Arthritis Rheumatol 2017; 69: 479 – 82.
dc.identifier.citedreferenceNeogi T, Mikuls TR. To treat or not to treat (to target) in gout [editorial]. Ann Intern Med 2017; 166: 71 – 2.
dc.identifier.citedreferenceHughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ. Monitoring of urate‐lowering therapy among US veterans following the 2012 American College of Rheumatology guidelines for management of gout. Ann Pharmacother 2017; 51: 301 – 6.
dc.identifier.citedreferenceAmerican College of Rheumatology endorsed measures. URL: https://www.rheumatology.org/Practice-Quality/Clinical-Support/Quality-Measurement/ACR-Endorsed-Measures.
dc.identifier.citedreferenceYazdany J, Myslinski R, Miller A, Francisco M, Desai S, Schmajuk G, et al. Methods for developing the American College of Rheumatology’s electronic clinical quality measures. Arthritis Care Res (Hoboken) 2016; 68: 1402 – 9.
dc.identifier.citedreferenceZhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63: 3136 – 41.
dc.identifier.citedreferenceSarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81: 925 – 34.
dc.identifier.citedreferencePerez‐Ruiz F, Alonso‐Ruiz A, Calabozo M, Herrero‐Beites A, Garcia‐Erauskin G, Ruiz‐Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545 – 9.
dc.identifier.citedreferenceRashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 2015; 42: 504 – 12.
dc.identifier.citedreferenceHalpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate‐lowering drug on serum urate and gout‐related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009; 25: 1711 – 9.
dc.identifier.citedreferenceHarrold LR, Andrade SE, Briesacher B, Raebel MA, Fouayzi H, Yood RA, et al. The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med 2010; 123: 54 – 9.
dc.identifier.citedreferenceSingh JA. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol 2014; 20: 172 – 4.
dc.identifier.citedreferenceRoddy E, Zhang WY, Doherty M. Concordance of the management of chronic gout in a UK primary‐care population with the EULAR gout recommendations. Ann Rheum Dis 2007; 66: 1311 – 5.
dc.identifier.citedreferenceCottrell E, Crabtree V, Edwards JJ, Roddy E. Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract 2013; 14.
dc.identifier.citedreferenceRomeijnders AC, Gorter KJ. Summary of the Dutch College of General Practitioners’ “gout” standard. Ned Tijdschr Geneeskd 2002; 146: 309 – 13. In Dutch.
dc.identifier.citedreferenceZhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301 – 11.
dc.identifier.citedreferenceZhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312 – 24.
dc.identifier.citedreferenceJordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372 – 4.
dc.identifier.citedreferenceKhanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431 – 46.
dc.identifier.citedreferenceKhanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 – 61.
dc.identifier.citedreferenceRichette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda‐Sanabria J, et al. 2016 updated EULAR evidence‐based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29 – 42.
dc.identifier.citedreferenceTonner C, Schmajuk G, Yazdany J. A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries. Curr Opin Rheumatol 2017; 29: 131 – 7.
dc.identifier.citedreferenceFitch KS, Bernstein S, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user’s manual. Santa Monica: Rand Corporation; 2001.
dc.identifier.citedreferenceAmerican College of Rheumatology. RISE (Qualified Clinical Data Registry) 2017. URL: http://www.rheumatology.org/I-Am-A/Rheumatologist/Registries/RISE.
dc.identifier.citedreferenceNational Quality Forum. NQF launches new path for eMeasure approval. 2017. URL: http://www.qualityforum.org/NQF_Launches_New_Path_for_eMeasure_Approval.aspx.
dc.identifier.citedreferenceQaseem A, McLean RM, Starkey M, Forciea MA, and the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017; 166: 52 – 7.
dc.identifier.citedreferenceMikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937 – 43.
dc.identifier.citedreferencePerez‐Ruiz F, Calabozo M, Pijoan JI, Herrero‐Beites AM, Ruibal A. Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356 – 60.
dc.identifier.citedreferenceBecker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful long‐term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36: 1273 – 82.
dc.identifier.citedreferenceBecker MA, Schumacher HR, Wortmann RL, Macdonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450 – 61.
dc.identifier.citedreferenceBecker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 1: 12.
dc.identifier.citedreferenceKhanna PP, Perez‐Ruiz F, Maranian P, Khanna D. Long‐term therapy for chronic gout results in clinically important improvements in the health‐related quality of life: Short Form‐36 is responsive to change in chronic gout. Rheumatology (Oxford) 2011; 50: 740 – 5.
dc.identifier.citedreferenceShoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321 – 5.
dc.identifier.citedreferenceLi‐Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577 – 80.
dc.identifier.citedreferencePascual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056 – 8.
dc.identifier.citedreferencePerez‐Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long‐term urate‐lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786 – 90.
dc.identifier.citedreferenceSundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez‐Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711 – 20.
dc.identifier.citedreferenceStrand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health‐related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol 2012; 39: 1450 – 7.
dc.identifier.citedreferenceBaraf HS, Becker MA, Gutierrez‐Urena SR, Treadwell EL, Vazquez‐Mellado J, Rehrig CD, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open‐label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 2013; 15: R137.
dc.identifier.citedreferenceDoherty M, Jenkins W, Richardson H, Abhishek A, Ashton D, Barclay C, et al. Nurse‐led care versus general practitioner care of people with gout: a UK community‐based randomised controlled trial. Ann Rheum Dis 2017; 76 Suppl 2: 167.
dc.identifier.citedreferenceBull PW, Scott JT. Intermittent control of hyperuricaemia in the treatment of gout. Adv Exp Med Biol 1989; 253A: 251 – 5.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr23500.pdf
Size:
301.4KB
Format:
PDF
View/Open
Name:
acr23500-sup-0001-AppendixS1.pdf
Size:
75.67KB
Format:
PDF
View/Open
Name:
acr23500_am.pdf
Size:
492.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.